Theralase Technologies Inc (TLTFF)

[123414]

Globe says Mackie rates Theralase "speculative buy"
TLTFF Speculative buy rating-Target price .60USD / .80CAD

(TLTFF) 0.1827 (+0.94%) 20/SEPT/19

2019-09-19 07:20 ET - In the News

The Globe and Mail reports in its Thursday, Sept. 19, edition that Mackie Research analyst Andre Uddin began coverage of Theralase Technologies (23.5 cents) with a "speculative buy" rating and 80-cent share target. The Globe's David Leeder writes in the Eye On Equities column that Mr. Uddin says in a note: "Theralase is focused on developing a paradigm-shifting Photodynamic Therapy (PDT) for treating Bacillus Calmete Guerin (BCG) -- unresponsive non-muscle invasive bladder cancer (NMIBC) -- targeting a significant market opportunity and unmet medical need (the only currently approved treatment option for patients is to have their bladder removed surgically or use Valrubicin). Theralase has completed a single-arm Phase Ib trial in 6 BCG-unresponsive NMIBC subjects. At the therapeutic dose, PDT induced a durable 67-per-cent Complete Response (CR) rate after one year -- far surpassing CR and duration of CR results of other bladder cancer treatment modalities, currently in development. Results to date have shown that Theralase's PDT was safe, well tolerated and at the therapeutic dose, effective, compared to other competitive drugs in development."
© 2019 Canjex Publishing Ltd. All rights reserved.

https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aTLT-2811319&symbol=TLT®ion=C